Research Progress on Pathogenic Mechanism and Potential Therapeutic Drugs of
Idiopathic Pulmonary Fibrosis Complicated with Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.101.45
- Author:
Ting XIAO
1
;
Jiali BAO
1
;
Xiangning LIU
2
;
Hui HUANG
3
;
Honggang ZHOU
1
Author Information
1. College of Pharmacy, Nankai University, Tianjin 300350, China.
2. Department of Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
3. Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Idiopathic pulmonary fibrosis;
Lung neoplasms;
Pathogenesis;
Therapeutic drug
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/genetics*;
Idiopathic Pulmonary Fibrosis/drug therapy*;
Lung Neoplasms/genetics*;
Lung/pathology*;
Signal Transduction
- From:
Chinese Journal of Lung Cancer
2022;25(10):756-763
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrous interstitial lung disease of unknown etiology. IPF is also considered to be among the independent risk factors for lung cancer, increasing the risk of lung cancer by 7% and 20%. The incidence of IPF complicated with lung cancer, especially non-small cell lung cancer (NSCLC), is increasing gradually, but there is no consensus on unified management and treatment. IPF and NSCLC have similar pathological features. Both appear in the surrounding area of the lung. In pathients with IPF complicated with NSCLC, NSCLC often develops from the honeycomb region of IPF, but the mechanism of NSCLC induced by IPF remains unclear. In addition, IPF and NSCLC have similar genetic, molecular and cellular processes and common signal transduction pathways. The universal signal pathways targeting IPF and NSCLC will become potential therapeutic drugs for IPF complicated with NSCLC. This article examines the main molecular mechanisms involved in IPF and NSCLC and the research progress of drugs under development targeting these signal pathways.
.
